Blood Res.  2016 Jun;51(2):139-142. 10.5045/br.2016.51.2.139.

Successful treatment of angioimmunoblastic T-cell lymphoma with clarithromycin

• Ohe M
• Hashino S

• KMID: 2309218
• DOI: http://doi.org/10.5045/br.2016.51.2.139

Abstract

No abstract available.

MeSH Terms

Clarithromycin*
Lymphoma, T-Cell*
T-Lymphocytes*
Clarithromycin

Figure

• 

  Fig. 1 Cervical computed tomography (CT) images. (A) Cervical CT reveals right cervical lymphadenopathy. (B) Cervical enhanced CT reveals considerable improvement in right cervical lymphadenopathy after 3 cycles of chemotherapy with tetrahydropyranyl doxorubicin (50 mg on day 1), cyclophosphamide (750 mg on day 1), vincristine (1.6 mg on day 1), and prednisolone (50 mg on days 1–5). (C) Cervical CT reveals complete resolution of the right cervical lymphadenopathy at 6 months after clarithromycin add-on therapy.

• 

  Fig. 2 Cervical histopathology and immunohistochemical images. (A) A right cervical lymph node biopsy specimen reveals effacement of the normal architecture with abundant pleomorphic cells and marked proliferation of arborizing high endothelial venules (hematoxylin and eosin stain, ×100). (B) Pleomorphic cells composed of lymphocytes, eosinophils, and atypical cells with intermediate-sized nuclei and clear cytoplasm are evident (hematoxylin and eosin stain, ×400). (C) Immunohistochemical examination shows CD3 positive staining in lymphocytes and atypical cells (×400). (D) A bone marrow aspiration smear reveals normal bone marrow (May-Giemsa stain, ×100).

Reference

1. Ishimatsu Y, Mukae H, Matsumoto K, et al. Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest. 2010; 138:730–733. PMID: 20822996.

2. Ohe M, Hashino S. A case of follicular B-cell lymphoma treated using clarithromycin. Korean J Hematol. 2011; 46:203–206. PMID: 22065978.

3. Ohe M, Hashino S, Hattori A. Successful treatment of diffuse large B-cell lymphoma with clarithromycin and prednisolone. Korean J Hematol. 2012; 47:293–297. PMID: 23320009.

4. Ohe M, Hashino S. Successful treatment with clarithromycin for Mixed phenotype acute leukemia, T/myeloid, NOS. Rinsho Ketsueki. 2010; 51:297–299. PMID: 20467229.

5. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010; 148:673–689. PMID: 19961485.

6. Dogan A, Ngu LS, Ng SH, Cervi PL. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia. 2005; 19:873–875. PMID: 15744336.

7. Matsumura Y, Kuroda J, Shimura Y, et al. Cyclosporine A and reduced-intensity conditioning allogeneic stem cell transplantation for relapsed angioimmunoblastic T cell lymphoma with hemophagocytic syndrome. Intern Med. 2012; 51:2785–2787. PMID: 23037475.

8. Ohe M, Hashino S. Successful treatment with erythromycin for idiopathic thrombocytopenic purpura. Korean J Hematol. 2011; 46:139–142. PMID: 21747888.

9. Wu L, Zhang W, Tian L, Bao K, Li P, Lin J. Immunomodulatory effects of erythromycin and its derivatives on human T-lymphocyte in vitro. Immunopharmacol Immunotoxicol. 2007; 29:587–596. PMID: 18075867.

10. Ratzinger F, Haslacher H, Poeppl W, et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Sci Rep. 2014; 4:7438. PMID: 25500904.

11. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004; 56:549–580. PMID: 15602010.

12. Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest. 2004; 84:1512–1519. PMID: 15311211.

13. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol. 2008; 19:396–397. PMID: 18245132.

14. Matsune S, Sun D, Ohori J, et al. Inhibition of vascular endothelial growth factor by macrolides in cultured fibroblasts from nasal polyps. Laryngoscope. 2005; 115:1953–1956. PMID: 16319604.

15. Saad AS, Shaheen SM, Elhamamsy MH, Badary OA. An open-label randomized controlled phase II study of clarithromycin (CL) plus CVP in patients (pts) with previously untreated stage III/IV indolent non Hodgkin lymphoma (NHL). J Clin Oncol (ASCO Annual Meeting Abstracts). 2014; 32(Suppl):abst e19510.